"The study found that over a 14-week period, incidence of HFSR—of any grade—was lower among patients who started using the urea-based cream at the start of treatment, compared to patients who received best supportive care alone."

According to first author, Dirk Schadendorf, MD, the study is “The first meta-analysis looking at Ipilimumab. It is also the largest analysis of melanoma patients ever conducted, with close to 5000 patients . . ."

“The question this study asked was: Can you end up transcending the poor prognosis associated with widespread disease distribution by using radical surgery to ultimately leave that person with no disease after you've finished? . . ."

"Often people have many questions and fears about the radiotherapy machine and treatment in general. Physicians . . . know that if the patient is anxious, there’s a strong chance it will continue throughout the therapy. It might even have clinical impact in that . . ."

"The phase II study found that patients who received the immunotherapy GVAX—which is administered with cyclophosphamide—plus immunotherapy CRS-207 had a significantly longer overall survival (OS) of 6.1 months, compared to an OS of 3.9 month among patients who received GVAX alone . . ."

A study in the Journal of Oncology Practice identified several building blocks that are essential in shifting a cancer center towards a more interdisciplinary model [and] offers a blueprint for other hospitals that wish to start multidisciplinary clinics.

The study found that when the score from the urinary PCA3 biomarker was considered alongside the PSA score, it resulted in a more refined measurement of risk for than could be provided with PSA alone, for both general cancer and high-grade cancer.

The study found that caregivers whose children or charges experienced five or more unexpected hospitalizations during the first to fifth year after diagnosis, and caregivers who had quit or changed jobs within that same time period reported a significantly higher financial burden . . .